– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive sleep apnea represents Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases – – Initiation of the trial anticipated in the first quarter of 2025 – RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Na ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-41614 MINERALYS THERAPEUTICS, INC. (Exact name of ...

Exhibit 99.1 Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, PA – Nove ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Rami Katkhuda - LifeSci Capital Matthew Caufield - H.C. Wainright Operator Greetings. Welcome to Mineralys Third Quarter 2024 Financial ...

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical c ...

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences. Guggenheim Healthcare Innovation Conference: Date: Tuesday, November 12, 2024 Time: 4:00pm EST Format: Fireside Chat Webcast ...

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024. Monday, November 11th @ 4:30 p.m. ET Domestic:1-877-407-9127Internation ...

I covered Mineralys (NASDAQ: MLYS ) in April last year. It had a few things going that got me interested: It was a new IPO, had just published positive phase 2 data, and it had a strong board of directors. The stock took a deep About the TPT service Thanks for reading. At the Total Pharma Tracker, we offer the following :- ing Balance (millior Projected American Shared Revenue Backlog $250 $213 $200 $150 $106 $104 $101 $100 $50 $0 12/31/21 12/31/22 12/31/23 5/10/24 (projected*) Ending Balance Date *This cha ...

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising-- NEW YORK--(PR NEWSWIRE)--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ: MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS. Investigation Details On August 13, 2024, Mineralys released its second quarter ...

LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ: MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Mineralys released its second quarter 2024 financial results ...